Deal Intelligence · IC cockpit

East Africa Precision Nutrition Ltd

Synthetic acquisition case · Premix and feed additives · Kenya / Tanzania / Uganda

Decision signal

Investigate before commitment

77 / 100

NPV

£10.6m

IRR

18.1%

MOIC

2.12×

EV / EBITDA

10.00×

Decisive unknown

The contractual status and true profitability of the largest customer. Nothing else in this assessment changes the answer as much.

What changes the decision?

The deal loses value below £0.1m normalised EBITDA or 6.47× exit multiple.

Evidence confidence51/100
ObservedModelledAssumption
Synthetic demonstration · important disclosure

East Africa Precision Nutrition Ltd is fictional. The company, transaction, financials and outputs are synthetic and illustrative. Nothing here is investment advice or a statement about a real business. The deterministic model uses only displayed inputs and assumptions, not generative AI or external facts.

Value creation

Five-year deal-return trajectory

£m · selected base scenario · hold-period exit in Y5

Scenario range

Return envelope — not probabilities

Transaction bridge

Price paid to modelled value

EV paid
Operating FCF
QoE adjustment
Concentration risk
Execution risk
Exit value
Net value

Sensitivity surface

Growth × normalised EBITDA NPV

Normalised EBITDA shift
Growth shift
-20%-10%0%+10%+20%

Every cell reruns the selected deterministic scenario. Hover for NPV, IRR and signal.

Driver analysis

Actual NPV impact around base

Exit multiple
3.118.1
Revenue growth
4.917.1
Synergy delivery
4.112.7
Discount rate
7.613.6
Normalised EBITDA
9.812.0
Working capital
10.310.9
Customer concentration
10.610.6

NPV £m · baseline 10.6

Decision thresholds

What changes the decision?

Normalised EBITDAValue turns negative below £0.1m
Maximum EVModel supports up to £150.0m
Minimum synergyAt least £0.0m run-rate
Customer concentrationEvidence score weakens above 22%Concentration is an evidence-risk threshold, not a cash-flow input.
Exit multipleBreak-even at 6.47×

Market architecture

TAM → SAM → SOM ranges

TAM£620780m
SAM£180240m
SOM£3452m

Company revenue £28.0m · all market ranges are synthetic assumptions requiring independent validation.

Country opportunity

Readiness × growth × addressable market

Kenya · evidence 66/100Tanzania · evidence 50/100Uganda · evidence 42/100

Risk constellation

Exposure versus evidence quality

Customer concentration

38

Exposure · evidence 51/100

Supplier dependency

68

Exposure · evidence 28/100

FX

62

Exposure · evidence 25/100

Regulatory transfer

55

Exposure · evidence 32/100

Working capital

48

Exposure · evidence 35/100

Evidence quality

49

Exposure · evidence 51/100

Customer concentration

A single account carries the share entered above. At 38% the loss of that account removes more EBITDA than the modelled synergies add.

Supplier dependency

Premix formulation depends on imported micro-ingredients from a small supplier set. Contract length and price-pass-through terms are unverified in this sample.

Regulatory and geographic exposure

Three regulators, three registration regimes and cross-border duty treatment. Product registration transfer on change of control is a live diligence item.

Evidence gaps

No audited accounts, no customer contracts, no plant utilisation data and no independent market study in this sample. Every figure here is synthetic.

IC context

Scenario changes & methodology

Inputs exactly as entered

Synergies ramp over three years

Bull

Premix is a formulation and service business, not a commodity. If the modelled margin survives a quality-of-earnings review and the top account is contracted, the buyer acquires regional registration coverage that would take years to build.

Bear

The entry multiple is paid for a margin that depends on one account and on imported inputs priced in hard currency. A single contract loss or an FX step-change moves the case below the entry price.

Decisive unknown

The contractual status and true profitability of the largest customer. Nothing else in this assessment changes the answer as much.

  1. 01The price is set against a margin that has not been independently verified; the assessment is a range, not a number.
  2. 02Modelled synergies are smaller than the EBITDA at risk in the largest customer account.
  3. 03Country attractiveness is not uniform: Kenya carries the revenue, Tanzania carries the growth, Uganda carries the distribution risk.
  4. 04Regulatory transfer on change of control is a timing risk to revenue, not only a legal formality.
  5. 05Evidence readiness, not market attractiveness, is the binding constraint on a confident recommendation.
Diligence questions
  1. Q1Show the contractual basis, pricing mechanism and renewal date for the largest customer account over the last three years.
  2. Q2Which input costs are imported, in which currency, and how has pass-through actually behaved in the last two price cycles?
  3. Q3What happens to product registrations, plant licences and distributor agreements on a change of control in each country?

Confidential diligence

Full report architecture

1. Transaction summary and assessed question
2. Deal snapshot and preliminary signal
3. Business model and revenue architecture
4. Market sizing: TAM, SAM, SOM
5. Demand drivers and country comparison
6. Scenario set and assumption changes
7. Transaction economics and sensitivity
8. Risk register and red flags
9. Headline findings and management questions
Advanced report modules18 locked

Available in a confidential Syntera diligence engagement.

10. Quality of earnings and normalisation schedule
11. Customer-level revenue and contract review
12. Supplier, input-cost and FX exposure analysis
13. Competitive landscape and share reconstruction
14. Pricing evidence and tender history
15. Plant capacity, utilisation and capex requirement
16. Working capital and cash conversion diagnostics
17. Regulatory dossier and registration transfer plan
18. Distribution and route-to-market assessment
19. Management assessment and retention structure
20. ESG, biosecurity and feed-safety review
21. Valuation triangulation: DCF, comparables, precedents
22. Synergy substantiation and integration cost
23. Downside protection and structuring options
24. Warranty, indemnity and earn-out design
25. 100-day integration plan
26. Exit pathways and buyer universe
27. Investment committee recommendation pack

Free users can adjust this synthetic sample and see the limited on-screen result. Raw-data downloads, saved projects, named-company analysis and full reports are Professional and Enterprise capabilities. Do not send confidential documents through this public page.

Assess my company or transaction

Observed, modelled and assumption-based figures remain distinct. When evidence is insufficient, Syntera identifies the gap rather than inventing certainty.